fbpx

Year

2017
They’re not yet 30 but have already shown outstanding talent, which is why these five brilliant scientists were awarded a Lundbeck Foundation Talent Prize on Monday evening. “There are many promising young scientists at the Danish universities but we don’t see exceptional talents every day, so it’s always a particular pleasure to award the Lundbeck...
They are among the most promising biomedical science researchers of their generation. Their research projects have the potential to revolutionise their fields. And they can now call themselves Lundbeck Foundation Fellows. Backed by 10 million Danish kroner they can dedicate the next five years to concentrated research. On Monday evening, five new Lundbeck Foundation Fellows...
BURLINGTON, MA, November 2, 2017 /PRNewswire/ — scPharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced that the 505(b)(2) New Drug Application (NDA) for Furoscix has been accepted for filing by the U.S....
November 1, 2017 CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $14.00...
Lund, Sweden, 08.00 CET, 2 November 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces the publication of its Interim Report January – September 2017. Q3 Net sales increased by 23% FINANCIAL HIGHLIGHTS...
Lund, Sweden, 18:00 CET 31st October 2017 – During October, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31st October 2017, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 49,900,591. For more information contact: Richard Davies, CEO Tel:...
EB8018 is an oral small molecule targeting the host-microbiome interaction by blocking FimH   PARIS and CAMBRIDGE, Massachusetts, October 27, 2017 /PRNewswire/ — ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce the successful completion of the first Phase 1 clinical study with its lead candidate EB8018, a small molecule designed to block...
Saint-Priest, France, October 27, 2017 – Biom’Up, specialist of surgical hemostasis, today provides a regulatory update regarding the United States Food and Drug Administration’s (FDA) review of the company’s Premarket Approval (PMA) application for its HEMOBLASTTM Bellows. The FDA conducted a PMA pre-approval inspection at the Biom’up Saint Priest, France, manufacturing facility. The four-day Premarket...
Press release Biom’Up announces the success of its IPO, raising close to €38.1 million on Euronext Paris First initial public offering in the healthcare sector on the Euronext regulated market in Paris in the last 6 months Strong institutional demand in France as well as abroad, especially in the United States and the United Kingdom:...
BIO Buzz Center with Ciara Kennedy – President & CEO, Amplyx Pharmaceuticals, Inc. at the 2017 BIO Investor Forum in San Francisco.
1 2 3 4 5 9

News

Professor wants to develop a radioactive precision missile to target brain cancer
21. February 2020
New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge